Critics of prescription drug copayment coupons contend that they force insurers to cover more expensive brand drugs and cause overall costs to rise. The counterpoint is notes that with rising drug copayments, coupons reduce patients’ out-of-pocket costs and provide access to needed therapies. The truth is more complex. (more…)
Healthcare policymakers need to understand not only the value of a new technology but how much it will cost the health system. A new framework provides clearer guidance for assessing the quality of budget impact analysis and cost-effectiveness analysis. (more…)
Schaeffer Initiative Senior Fellow Matthew Fielder analyzes the potential effects of the Senate’s health care bill on essential health benefits and ACA protections against catastrophic costs.
Weakening essential health benefit standards could also have important negative consequences for the coverage offered by employers of all sizes because it would weaken the ACA’s guarantee of protection against catastrophic costs. (more…)
We estimate that premiums would be around 13 percent higher under the AHCA than they are under current law, holding plan generosity and the individual market age distribution fixed at their current law levels. (more…)
Read our four-step market-based proposal that is consistent with many of the president’s remarks on health care and, importantly, with many core Democratic principles on health care too. (more…)
More than a dozen states have enacted various protective measures to protect patients from surprise medical bills. This post outlines why federal action is needed and recommendations on how to move forward. (more…)